Why Novo Nordisk missed its sales estimates on weight-loss drug Wegovy: CEO
Novo Nordisk's (NVO) investors are worried its competition with Eli Lilly (LLY) is heating up and that the first-to-market GLP-1 leader is losing ground.
Even with 72% of the global market share, the competition in the US has been pressuring the company's stock in recent months. It is no longer Europe's most valuable company, and the stock is down more than 22% year to date. Lilly's Zepbound overtook Novo's Wegovy as the leading obesity drug, according to the latest prescription data last month.
But Novo CEO Lars Jørgensen attributes the softness in sales to the copycats from compounding pharmacies, which have been allowed on the market due to the shortage that constrained the market in the past couple of years.
The compounding business is "approximately as big as our own business, which is quite surprising in many ways," Jørgensen told Yahoo Finance in an interview Wednesday. Novo reported Wegovy and Ozempic combined sales of more than $7.5 billion.
Overtaken? The Wegovy injectable packaging. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images)
·
UCG via Getty Images
There is no public data available about the revenues and market size for compounding, but a 2024 estimate from the Outsourcing Facilities Association, the trade group representing compounding pharmacies, showed 80 million prescriptions for copycat semaglutide were filled in the past year.
That, Jørgensen said, is why the company missed its Wegovy sales estimates by 7% in first quarter earnings Wednesday.
The good news: The FDA recently removed semaglutide — the key ingredient in Wegovy — from its shortage list, which is why Novo has forecast relief in the second half of the year. But it still cut its sales guidance by 3%.
Boost access to boost sales
Meanwhile, Novo has been busy forging deals with telehealth platforms, like Hims & Hers (HIMS), to increase access to Wegovy.
Novo also scored an exclusive deal to be listed as the preferred weight-loss drug for coverage on CVS's (CVS) formulary. This caused Lilly's stock to tank last week, but Jørgensen said CVS approached his company for the deal, not the other way around.
"We have not made a bid for an exclusive position," he said.
Investors worried it would launch a price war.
"Some have been worried a price war was coming up; we are not going for that. We believe in choice for physicians and patients," Jørgensen said.
But will it help boost prescriptions for Wegovy? Investors are waiting to find out.
Jørgensen said his goal is to meet the patients where they are, as they showed a propensity toward any and all available access points and were willing to pay cash.
That's also why CVS, in addition to the formulary, is going to offer Wegovy for $499 per month for cash-paying customers, the same price available through the telehealth platforms.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@
Yahoo
3 hours ago
- Yahoo
Common Childhood Virus Linked to Alzheimer's Development in Old Age
A study published 30 years ago is striking up new conversation about the potential connection between the common cold sore and Alzheimer's disease. Published in The Lancet in 1997, researchers compared DNA extracted from the brains of elderly people with and without Alzheimer's, and in some of them, found herpes simplex virus 1 (HSV-1)—an infection often contracted in childhood—dormant in the nerves. Ultimately, researchers predicted that those with HSV-1 and a specific gene, called the ApoE-e4 gene, had a higher risk of developing Alzheimer's. Meet the Experts: David Hunter, M.D., an assistant professor and neurologist with UTHealth Houston, Linda Yancey, M.D., an infectious disease doctor at Memorial Hermann Health System; and Mark Santos, Ph.D., an assistant professor of microbiology and immunology at Touro University Nevada. Study co-author Ruth Itzhaki, Ph.D., summarized her team's findings in a recent article for The Conversation and noted that, over the years, additional work has surfaced to support hers. But what does it all mean, exactly? If a cold sore pops up, should you be concerned about dementia? We reached out to experts who explained everything. 'HSV-1 is a common virus to which almost everyone is exposed early in life,' says David Hunter, M.D., an assistant professor and neurologist with UTHealth Houston. 'It is best known for causing cold sores and is closely related to chicken pox and mononucleosis.' What these viruses have in common is that they are neurotropic, meaning they linger in the nervous system long after the initial illness, explains Linda Yancey, M.D., an infectious disease doctor at Memorial Hermann Health System, and can be reactivated by stress or lowered immunity. That's how, for instance, chicken pox can manifest later in life as shingles, adds Dr. Hunter. The virus's ability to infiltrate the nerves is believed to get it past the blood-brain barrier, a membrane that shields the organ from infection via the bloodstream. Thanks to that entry point, Dr. Hunter says, HSV-1 is the most common cause of viral brain inflammation in the United States. 'There is no vaccine for HSV and almost everyone will get it by adulthood,' Dr. Hunter adds. Cold sores are a mild case of it, and symptoms can be treated with antiviral drugs. Dormant HSV-1 may be reactivated by illness and reach the brain, explains Mark Santos, Ph.D., an assistant professor of microbiology and immunology at Touro University Nevada. This can trigger brain inflammation over time, known as herpes encephalitis,and in people with genetic risk factors, like the ApoE-4 gene, contribute to Alzheimer's development, he adds. 'We don't entirely know why ApoE-4 is a risk factor for Alzheimer's,' adds Dr. Hunter. 'The link to HSV could be that ApoE-4 impacts the blood-brain barrier and makes it easier for HSV to enter.' And the inflammation caused by that entry may heighten Alzheimer's risk. 'It is now universally accepted that inflammation in the brain is a key step in the development of Alzheimer's,' Dr. Hunter reiterates. In the three decades since the original study, doctors and researchers have learned much more about Alzheimer's disease and its connection to viral inflammation. For instance, several studies have found that being immunized for any disease (like COVID-19 or the flu) reduces Alzheimer's risk, says Dr. Hunter. 'Several other studies have shown that reducing inflammation in the brain helps prevent Alzheimer's,' he adds. Santos concurs. 'Since 1996, additional studies have found HSV-1 DNA in the brains of individuals with Alzheimer's. Lab studies have also shown that HSV-1 infection can trigger the buildup of amyloid-beta and tau—proteins strongly associated with Alzheimer's pathology,' he explains. However, there are a few disclaimers to note. Firstly, the posed risk is associated with people who contract HSV-1 in early life, giving it time to progressively cause inflammation. The risk may be lower in adults, says Santos. 'That said, if someone has other risk factors (like a weakened immune system or APOE-e4), adult-onset HSV-1 could still have long-term consequences,' he adds. Still, neurotropic viruses are extremely common, Dr. Yancey reiterates. 'This makes it difficult to tease out whether they are causing neurologic problems or are simply common in the general population, including people with neurologic problems,' she adds. In other words, because most people end up with HSV-1 doesn't necessarily mean that most people will get Alzheimer's. 'Most cold sores aren't a cause for concern,' Santos adds. 'They're common and usually well-controlled by the immune system. But for people with frequent outbreaks, weakened immunity, or APOE-e4, it may be worth discussing with a healthcare provider. The concern is not a single cold sore, but long-term viral activity in the brain.' More research, including long-term studies, is needed to make any solid associations, Santos and Dr. Yancey conclude. 'The current data is based on population-level surveys. There is no way to predict on an individual patient's level whether this has a meaningful impact,' says Dr. Yancey. Future research will, hopefully, at least help experts understand how antiviral treatment affects Alzheimer's risk, as well as identify better ways to detect when HSV-1 is active in the brain. 'The hope is that understanding how infections contribute to Alzheimer's will open up new ways to prevent or treat it—especially before symptoms start,' says Santos. Being vaccinated, exercising, engaging in mental stimulation, and maintaining a heart-healthy diet are all known ways to lower dementia risk, our experts say. Avoiding smoking or nicotine use of any kind can also 'drastically' reduce the risk, says Dr. Yancey. All of these habits and choices work together to support both immune and brain health. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Yahoo
3 hours ago
- Yahoo
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Eli Lilly (NYSE:LLY) lands an $870 million pact with Camurus (CAMX) to build long-acting obesity treatments, tapping FluidCrystalslow-release tech to stretch dosing from days to weeks. Lilly's team will work hand-in-glove with Camurus engineers, adapting the gel-matrix delivery platformalready proven in other therapiesto Lilly's top weight-loss candidates, including Zepbound. Instead of daily or weekly shots, patients could look forward to a monthly injection or even a once-daily pill that behaves like a slow-release depot. The deal kicks off with an upfront payment and scales into development and commercialization milestones, keeping Lilly's risk in check while aligning both firms on successful trial readouts. This move comes as Lilly races against rivals in the booming obesity marketnow set to exceed $50 billion by 2030and follows its own push for an oral GLP-1 option to rival injectables. By offering less-frequent dosing, Lilly hopes to tackle patient drop-off and win market share from peers like Novo Nordisk. Plus, the modified release format could open doors to new payer contracts, since fewer doses often translate to better adherence and lower overall costs. Why It Matters: Extended-release obesity drugs could revolutionize treatment by cutting patient burden and boosting lifetime revenue. Lilly's bet on Camurus' delivery system underscores its commitment to leading the metabolic disease space rather than just competing on molecule potency. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
